Niki BioSolutions, Inc. entered into an At the Market Offering Agreement on October 9, 2026, with H.C. Wainwright & Co., LLC and Brookline Capital Markets, a division of Arcadia Securities, LLC. The agreement allows the company to sell shares of its common stock from time to time through the sales agents. The offering has a maximum aggregate offering price of up to $1,396,000, subject to the availability of authorized but unissued shares and the company's continued eligibility for use of Form S-3.
The offering is conducted pursuant to a shelf registration statement on Form S-3 (File No. 333-298608), initially filed on August 28, 2026, and declared effective on October 9, 2026. The sales agents will sell shares at the market price on the applicable trading market. The company has the right to designate the maximum amount of shares to be sold on any trading day and the minimum price per share. The company is not obligated to sell any shares under the agreement and may suspend the offering at any time.
Wainwright will receive a placement fee equal to 3.0% of the gross sales price of shares sold as a sales agent. Brookline acts as a "qualified independent underwriter" to address a conflict of interest, as Dr. Kira Sheinerman, the company's largest shareholder and a director, is a managing director at Wainwright. Brookline will provide this service without additional compensation, and the company has agreed to indemnify Brookline against certain liabilities.
